HHS announces initiative to help uninsured and underinsured in US access bebtelovimab COVID-19 monoclonal antibody treatment; HHS making 60,000 doses available for providers who use commercial bebtelovimab to treat uninsured, underinsured patients

Sample article from our Health Care Sector

September 27, 2022 (press release) –

Efforts will help smooth transition of outpatient treatment bebtelovimab to commercial marketplace

The U.S. Department of Health and Human Services (HHS) today announced a new effort to help uninsured and underinsured Americans access the COVID-19 monoclonal antibody treatment bebtelovimab even after the product became available on the commercial market last month.

Bebtelovimab received FDA emergency use authorization in February 2022. Since then, the U.S. government has purchased more than 750,000 doses of the product. Throughout the pandemic, bebtelovimab, along with other COVID-19 therapeutics, have been provided to states and territories for free. While the federal government has always expected that bebtelovimab and other COVID-19 therapeutics would ultimately transition to the commercial market, the timeline to make the transition for bebtelovimab has accelerated without additional funding from Congress. As a result, the federal procurement and distribution of bebtelovimab began to phase out and the product became available on the commercial market on August 17.

HHS is making 60,000 doses of the product available to support the bebtelovimab product replacement initiative. Through this new initiative, which is effective immediately, health care providers who use a commercially procured dose of bebtelovimab to treat an uninsured or underinsured patient may be eligible to have the dose replaced for free by HHS. Health care providers can use their own established methods for determining uninsured or underinsured status, such as eligibility criteria for existing programs for which a patient may already be eligible. At the current rate of use, the additional doses purchased for this initiative are expected to be available through September 2023.

Approximately 8% of Americans are not covered by a government insurance program such as Medicare or Medicaid or by private insurance. The Medicare and Medicaid programs fully cover all costs for bebtelovimab treatment, and the therapeutic is likely to be covered under most private health insurance plans.

Bebtelovimab is available under emergency use authorization from the U.S. Food and Drug Administration as a treatment product to reduce hospitalization and death among patients who have a positive COVID-19 test and are at high risk for progression to severe COVID-19 and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.


* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.